CareLit · DOI-Nachweis · Pneumologie
Once-daily tiotropium Respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma
DOI 10.1055/s-0035-1544684
Bibliografische Angaben
Nachweis in CareLit
Autor:innenO Schmidt, D Halpin, E Bateman, P Paggiaro, E Bleecker, M Engel, P Moroni-Zentgraf, H Schmidt, H Kerstjens
ZeitschriftPneumologie
Ausgabe02/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: A reduction in asthma exacerbation risk may provide improvements in clinical burden, patient experience and healthcare costs. In Phase III trials, once-daily tiotropium Respimat (tioR) add-on to at least ICS improved lung function in symptomatic asthma patients. We investigated exacerbation risk in each trial. Methods: Five Phase III double-blind, placebo-controlled, parallel-group trials in patients wit…
Zitieren
Zitierempfehlung
O Schmidt, D Halpin, E Bateman, P Paggiaro, E Bleecker, M Engel, P Moroni-Zentgraf, H Schmidt, H Kerstjens (2015) Once-daily tiotropium Respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma. Pneumologie (02). https://doi.org/10.1055/s-0035-1544684
Mit CareLit weiterarbeiten